We are extremely proud of Kim Rodriguez, Alfred M. MacDaniel, Jr, and the entire Acessa Health team!
This acquisition is an exciting opportunity for a passionate team of women’s health entrepreneurs. With Hologic’s commercial infrastructure, Acessa’s innovative treatment for symptomatic uterine fibroids will more rapidly become the standard of care, providing better clinical outcomes for millions of women.
Congrats also to our co-investors Ian Ratcliffe with Sands Capital Ventures and Joe Andrasko with Fry’s Path Capital.